Michael Weiser

Michael Weiser was the founder of Foresight Biotherapeutics, Inc. (2008, Chief Executive Officer & Director), Actin Biomed LLC (2006, Co-Chairman), and Actin Capital LLC (2006, Co-Chairman).
Current jobs include Independent Director at Emisphere Technologies, Inc. (since 2005), Independent Director at Iovance Biotherapeutics, Inc. (since 2018), and Member of the American Society of Clinical Oncology, Inc., Alpha Omega Alpha Honor Medical Society, American Society of Hematology, The Association for Research in Vision & Ophthalmology, and The National Medical Honor Society.
Former jobs include Chairman at Ivory Capital Corp., Chairman at Chelsea Therapeutics International Ltd. (2012-2014), Director at VioQuest Pharmaceuticals, Inc. (2003-2009), Director of Research at Paramount BioCapital Asset Management, Inc. (2001-2002), Director at TG Therapeutics, Inc. (2003-2010), Research Director at Paramount BioCapital, Inc. (1998-2006), Director at ZIOPHARM, Inc. (2003-2005), Director at Alacrity Biosciences, Inc., Director at Talon Therapeutics, Inc. (2002-2010), Independent Director at Alaunos Therapeutics, Inc. (2005-2018), Research Director at Paramount BioSciences LLC (2006), Executive Vice President at Paramount Acquisition Corp.
(2005-2008), and President & Secretary at Seward Sciences, Inc. (2008).
Education includes an undergraduate degree from the University of Vermont (1987), a doctorate from Weill Cornell Medical College, and a doctorate from New York University School of Medicine (1996).